甲氨蝶呤联合阿达木单抗治疗早期类风湿性关节炎患者的效果及对血清CD206含量的影响  

The Effect of Methotrexate Combined with Adalimumab in the Treatment of Patients with Early Rheumatoid Arthritis and Its Effect on Serum CD206 Levels

作　　者：孙康文[1] 罗刚[1] SUN Kang-wen;LUO Gang(Department of Orthopedics,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院骨科,重庆400016

出　　处：《医学信息》2020年第23期141-143,共3页Journal of Medical Information

摘　　要：目的分析甲氨蝶呤联合阿达木单抗治疗早期类风湿性关节炎患者的效果及对血清CD206含量的影响。方法选取2015年6月~2019年6月我院治疗的150例早期类风湿性关节炎患者作为研究对象,按照随机数字表法分为研究组和对照组,每组75例。对照组予以甲氨蝶呤和安慰剂治疗,研究组予以甲氨蝶呤联合阿达木单抗治疗,比较两组用药前、用药后3、6、12、24个月血清CD206表达水平及类风湿性关节炎病情变化情况。结果治疗后6、12、24个月,研究组CD206含量低于对照组,差异有统计学意义(P<0.05)。研究组关节腔内注射糖皮质激素次数为(9.62±4.23)次,与对照组的(9.77±4.28)次比较,差异无统计学意义(P>0.05)。两组治疗后3个月CRP、关节肿痛数及VAS评分较治疗前降低,差异有统计学意义(P<0.05);但组间比较,差异无统计学意义(P>0.05);两组治疗后6、12个月CRP、关节肿痛数及VAS评分较治疗前降低,且研究组低于对照组,差异有统计学意义(P<0.05)。结论甲氨蝶呤联合阿达木单抗治疗能降低早期类风湿性关节炎患者CD206水平及疾病活动指数,缓解患者疼痛症状。Objective To analyze the effect of methotrexate combined with adalimumab in the treatment of patients with early rheumatoid arthritis and its influence on serum CD206 levels.Methods The study included 150 patients with early rheumatoid arthritis who accepted treatment in our hospital from June 2015 to June 2019,and they were divided into study group(75 cases)and control group(75 cases),randomly.Patients in study group were treated with methotrexate and atamuzumab,and the patients in control group were treated with methotrexate and placebo.Serum CD206 levels and rheumatoid arthritis activity were compared between the two groups before and after medication at 3,6,12 and 24 months.Results At 6,12,and 24 months after treatment,the CD206 content of the study group was lower than that of the control group,the difference was statistically significant(P<0.05).The number of intra-articular injections of glucocorticoids in the study group was(9.62±4.23)times,compared with(9.77±4.28)times in the control group,the difference was not statistically significant(P>0.05).3 months after treatment,CRP,joint swelling and pain,and VAS score were lower in the two groups than before treatment,the difference was statistically significant(P<0.05);but there was no statistically significant difference between the two groups(P>0.05);At 6 and 12 months after treatment,CRP,joint swelling and pain,and VAS score were lower than before treatment,and the study group was lower than the control group,the difference was statistically significant(P<0.05).Conclusion The treatment of methotrexate combined with adalimumab can reduce the CD206 level and disease activity index of patients with early rheumatoid arthritis,and relieve the pain symptoms of patients.

关 键 词：类风湿性关节炎 抗肿瘤坏死因子Α CD206 

分 类 号：R593.22[医药卫生—内科学]